LumiraDx’s Broad Menu of Lab Comparable Results on Single, Portable Diagnostic Platform Promises to Transform Community Care
Posted on 13 Nov 2021
LumiraDx (London, UK) is offering a broad menu of lab comparable results on the LumiraDx Platform, its next generation point of care diagnostic system, that aims to transform community care.
The LumiraDx Platform combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. The platform is designed to go wherever the patient is, whether this is in a hospital, medical office, pharmacy, or in other non-traditional settings such as schools or airports. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care. The company has a pipeline of more than 30 assays, initially focused on some of the most common conditions being diagnosed or managed with POC testing such as coagulation disorders, infectious diseases, cardiovascular and diabetes.
LumiraDx has developed SARS-CoV-2 antigen and antibody tests that provide lab comparable results for COVID-19 testing in minutes on a single platform. The LumiraDx SARS-CoV-2 Ag Test on the LumiraDx platform enables physicians to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection. Similarly, the LumiraDx SARS-CoV-2 Ab Test is designed to be used in community care settings to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The company also offers the SARS-CoV-2 Ag Surveillance Test for environments such as schools and workplaces that allows simultaneous testing of up to five samples on its platform with cost per sample as low as USD 4. With digital results in less than 12 minutes from sample application and a comprehensive connectivity solution, it is designed to measure population health metrics in real-time to help prevent the spread of infection using the LumiraDx affordable, easy-to-use, onsite testing platform.
The LumiraDx Platform menu also includes point of care tests for INR and D-Dimer with high levels of accuracy comparable to central lab-based tests. The LumiraDx INR Test measures prothrombin time reported as International Normalized Ratio (INR) from a single, direct fingerstick blood sample - all in less than 90 seconds. The LumiraDx D-Dimer Test is an easy to use fluorescence immunoassay designed to rapidly quantify D-Dimer levels in human whole blood and plasma at the point of care. It is the first quantitative micro-fluidic immunoassay of its kind, providing a precise and accurate D-Dimer result from a single direct fingerstick blood sample, in only six minutes. All point of care tests on the LumiraDx Platform menu have achieved CE Mark and are commercially available in Europe.
Related Links:
LumiraDx
